Blackstone Injects $250 Million into Anagram’s Oral Biotech Pill Program
Blackstone has committed $250 million to Anagram’s new financing round, securing preferred equity to support the startup’s one-pill therapeutic candidate. The capital will fund IND-enabling studies and Phase 1 human trials for the oral treatment scheduled to begin in late 2026.
1. Blackstone Announces $250M Investment
Blackstone has committed $250 million to Anagram’s new financing round, securing preferred equity to support the company’s launch. The terms grant Blackstone board representation as it takes a significant ownership position.
2. Funding to Advance Oral Biologic Candidate
Anagram is developing an oral peptide-based therapy designed for once-daily dosing to treat a chronic condition with high unmet medical need. Proceeds will underwrite IND-enabling studies and Phase 1 trials slated for late 2026.
3. Strategic Significance for Blackstone
This transaction marks one of Blackstone’s largest venture bets in biotech, adding to its $10 billion healthcare allocations. A successful clinical readout could enhance portfolio valuations and drive follow-on capital commitments.